{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_bimekizumab",
          "name": "Bimekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ixekizumab",
          "name": "Ixekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_tazarotene",
          "name": "Tazarotene"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.1
        },
        "graph_signals": {
          "support_weight": 4.55,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": [
            {
              "topic": "Acitretin Safety",
              "pro": [
                "n_adv_acitretin"
              ],
              "con": [
                "H1"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin 可作用于免疫反应，与炎症通路相关"
          ],
          "safety_risk": [
            "潜在的旁路作用对安全性产生重要影响"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "需进一步验证Acitretin在该病症中的疗效"
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.78,
        "components": {
          "mechanism_fit": 0.9,
          "class_prior": 0.7,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.8,
          "safety_risk": 0.2,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.1
        },
        "graph_signals": {
          "support_weight": 5.25,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab 有针对 TNF-α 的有效机制"
          ],
          "indication_plausibility": [
            "临床数据支持Adalimumab在特定病症中的疗效"
          ]
        },
        "confidence": "high",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H3",
        "score": 0.61,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 3.55,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Apremilast 通过抑制炎症反应机制发挥作用"
          ],
          "indication_plausibility": [
            "有临床研究支持其在炎症性皮肤病中的应用"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H4",
        "score": 0.68,
        "components": {
          "mechanism_fit": 0.8,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.1
        },
        "graph_signals": {
          "support_weight": 4.25,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Bimekizumab 的 IL-17 促进抗炎功效"
          ],
          "indication_plausibility": [
            "有临床试验数据支持其效果"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H5",
        "score": 0.65,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 4.0,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Brodalumab 能有效针对 IL-17A"
          ],
          "indication_plausibility": [
            "有研究支持其在相关疾病中的应用"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H6",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Cyclosporine 的免疫抑制作用"
          ],
          "indication_plausibility": [
            "对于某些患者可能有效，但疗效不一致"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H7",
        "score": 0.71,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.7,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 4.25,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept 可有效抑制炎症"
          ],
          "indication_plausibility": [
            "在PSA中显示出效果"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H8",
        "score": 0.67,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 4.0,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ixekizumab 有针对性的作用于 IL-17E"
          ],
          "indication_plausibility": [
            "针对皮肤病有支持性的临床数据"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H9",
        "score": 0.6,
        "components": {
          "mechanism_fit": 0.55,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 3.5,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate 在慢性炎症条件下有效"
          ],
          "indication_plausibility": [
            "传统药物有基础疗效"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H10",
        "score": 0.64,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 3.5,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab 专门针对 IL-17A"
          ],
          "indication_plausibility": [
            "可期待的效果在临床上有支持"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H11",
        "score": 0.5,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 2.5,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Tazarotene 主要是局部作用"
          ],
          "indication_plausibility": [
            "适用于局部治疗"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      },
      {
        "hypothesis_id": "H12",
        "score": 0.63,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 3.5,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab 特异性靶向 IL-12/23"
          ],
          "indication_plausibility": [
            "支持慢性病例的治疗效果"
          ]
        },
        "confidence": "medium",
        "uncertainties": []
      }
    ],
    "ranking": [
      "H2",
      "H7",
      "H4",
      "H8",
      "H5",
      "H10",
      "H12",
      "H3",
      "H9",
      "H6",
      "H1",
      "H11"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_bimekizumab",
          "type": "Drug",
          "label": "Bimekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tazarotene",
          "type": "Drug",
          "label": "Tazarotene",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_immune_response",
          "type": "Target",
          "label": "Immune Response",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_symptomatic_relief",
          "type": "Phenotype",
          "label": "Symptomatic Relief",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_remission",
          "type": "Phenotype",
          "label": "Skin Remission",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "Acitretin Off-Target",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "Acitretin Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "Adverse Effects of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Bimekizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Tazarotene",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "常用治疗在免疫调节上有效"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向 TNF-α 的治疗策略"
        },
        {
          "source": "drug_apremilast",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "抑制炎症通路的机制"
        },
        {
          "source": "drug_bimekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17靶向作用"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A拮抗剂"
        },
        {
          "source": "drug_cyclosporine",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "免疫抑制机制支持"
        },
        {
          "source": "drug_etanercept",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "抑制炎症反应"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17E 的抵抗并促进重建"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "作为传统治疗药物的有效性"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对 IL-17A 的特异性干预"
        },
        {
          "source": "drug_tazarotene",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "调控分化的机制"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向 IL-12/23 的选择性"
        },
        {
          "source": "target_immune_response",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "支持的通路连接"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "与通路在病理过程中的一致性"
        },
        {
          "source": "drug_acitretin",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "已知的临床表现改善"
        },
        {
          "source": "drug_adalimumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "有效性证据强"
        },
        {
          "source": "drug_apremilast",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "机制的有效性总结"
        },
        {
          "source": "drug_bimekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "靶向的有效性"
        },
        {
          "source": "drug_brodalumab",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "支持的临床证据"
        },
        {
          "source": "drug_cyclosporine",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "提高患者群体的好转率"
        },
        {
          "source": "drug_etanercept",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "发挥快速生效"
        },
        {
          "source": "drug_ixekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对于根据临床效果获得改善"
        },
        {
          "source": "drug_methotrexate",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "已知的改善作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "可期待的病理改善"
        },
        {
          "source": "drug_tazarotene",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "局部疗法已知效果"
        },
        {
          "source": "drug_ustekinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "支持慢性病例治疗的有效性"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路作用导致不良反应"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能通过非靶向途径导致风险"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在此风险，则抵消潜在疗效"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "score": 0.78,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Adalimumab对TNF-α的强效机制",
          "在治疗特定病症中的临床有效性得到数据支持"
        ],
        "caveats": [
          "疗效依赖于患者的具体临床情况"
        ],
        "confidence": "high"
      },
      {
        "hypothesis_id": "H7",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "score": 0.71,
        "graph_snapshot_ref": "GE_H7_round4",
        "key_assumptions": [
          "Etanercept可以有效抑制炎症",
          "在相关病症中证明其有效性"
        ],
        "caveats": [
          "长期疗效和安全性需要进一步观察"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_bimekizumab",
          "name": "Bimekizumab"
        },
        "score": 0.68,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "IL-17靶向作用可促进抗炎功效",
          "有临床试验支持其效果"
        ],
        "caveats": [
          "新药的长期安全性尚不明确"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Immune Response→Inflammatory Response Pathway→Generalised pustular psoriasis",
          "reason": "明确的机制路径与临床相应的有效性"
        }
      ],
      "remaining_gaps": [
        "对Acitretin的安全性问题需明确更多证据"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B"
          ],
          "impact_summary": "引入新的靶向药物，有助于提升整体候选药物的多样性"
        },
        {
          "round": 2,
          "seeds": [
            "C",
            "D"
          ],
          "impact_summary": "补充了对皮肤病有效的候选药物"
        }
      ],
      "lessons": [
        "疗效支持同类药物应定期更新以反映新数据",
        "优先考虑机制独特且临床有效的药物"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "优先明确临床疗效与安全性之间的联系"
      },
      {
        "role": "Skeptic",
        "patch": "对可能的安全风险进行可证伪的分析，并明确标注"
      },
      {
        "role": "Explorer",
        "patch": "聚焦在已知有效药物的新的机制与潜在应用"
      }
    ],
    "heuristics": [
      {
        "when": "愈合相关表型",
        "then": "必须比较短期与长期疗效"
      },
      {
        "when": "免疫逻辑",
        "then": "考虑不同药物在激活或抑制免疫反应上的效果"
      }
    ]
  }
}